Retroprosthetic membranes in AlphaCor patients: Risk factors and prevention

Cornea

Volumn 24, Issue 6, 2005, Pages 692-698

  Hicks, Celia R ^a,c   Hamilton, Stephen ^b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b PIEDMONT HOSPITAL   (United States)

^c LIONS EYE INSTITUTE   (Australia)

Author keywords

AlphaCor artificial cornea; Biointegration; Histology; Prevention; Retroprosthetic membrane; Risk factors

Indexed keywords

ARTIFICIAL ORGAN; CONTROLLED STUDY; DIABETES MELLITUS; HISTOPATHOLOGY; HUMAN; HYDROGEL; HYPERTENSION; KERATOPROSTHESIS; MAJOR CLINICAL STUDY; POSTOPERATIVE CARE; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROSTHESIS FAILURE; RACE; RETROPROSTHESIS MEMBRANE; REVIEW; RISK ASSESSMENT; RISK FACTOR;

ADULT; AGED; AGED, 80 AND OVER; ARTIFICIAL ORGANS; CORNEA; CORNEAL DISEASES; DRUG THERAPY; FEMALE; HUMANS; MALE; MEMBRANES; MIDDLE AGED; OPHTHALMOLOGIC SURGICAL PROCEDURES; POSTOPERATIVE COMPLICATIONS; PROSTHESES AND IMPLANTS; PROSTHESIS IMPLANTATION; RISK FACTORS;

EID: 23044491586     PISSN: 02773740     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ico.0000154380.13237.ea     Document Type: Review

References (43)

1. Hicks CR, Chirila TV, Clayton AB, et al. Clinical results of implantation of the Chirila keratoprosthesis in rabbits. Br J Ophthalmol. 1998;82: 18-25.
2. Johnson RN, Balyeat E, Stern W. Heparin prophylaxis for intraocular fibrin. Ophthalmology. 1987;94:597-601.
3. Chirila TV, Vijayasekaran S, Home R, et al. Interpenetrating polymer network (IPN) as a permanent joint between the elements of a new type of artificial cornea. J Biomed Mater Res. 1994;28:745-753.
4. Hicks C, Crawford G, Chirila T, et al. Development and clinical assessment of an artificial cornea. Prog Retina Eye Res. 2000;19:149-170.
5. Crawford GJ, Hicks CR, Lou X, et al. The Chirila keratoprosthesis: phase I human clinical trial. Ophthalmology. 2002;109:883-889.
6. Hicks CR, Crawford GJ, Lou X, et al. Corneal replacement using a synthetic hydrogel cornea, AlphaCor device, preliminary outcomes and complications. Eye. 2003;17:385-392.
7. Hicks CR, Crawford GJ. Indications and technique: AlphaCor artificial cornea. Tech Ophthalmol. 2003;1:151-155.
8. Hicks CR, Crawford GJ. Melting after keratoprosthesis implantation: The effects of medroxyprogesterone. Cornea. 2003;22:497-500.
9. Chiou AG-Y, Chang C, Chang C, et al. Characterisation of fibrous rerrocorneal membrane by confocal microscopy Cornea. 1998;17: 669-671.
10. Perlman M, Baum JL, Kaye GI. Fine structure and collagen synthesis activity of monolayer cultures of rabbit corneal endothelium. J Cell Biol. 1974;63:306-311.
11. Sebestyen JG. Fibrinoid syndrome: a severe complication of vitreous surgery. Ann Ophthalmol. 1982;14:853-856.
12. Shinoda K, Ishida S, Kawashima S, et al. Comparison of the levels of hepatocyte growth factor and vascular endothelial growth factor in aqueous fluid and serum with grades of retinopathy in patients with diabetes mellitus. Br J Ophthalmol. 1999;83:834-837.
13. Wunderlich K, Senn BC, Reiser P, et al. Connective tissue growth factor in retrocorneal membranes and corneal scars. Ophthalmologica. 2000;214: 341-346.
14. Onodera T, Gimbel HV, DeBroff BM. Effects of cycloplegia and iris pigmentation on postoperative intraocular inflammation. Ophthalmic Surg. 1993;24:746-752.
15. El-Harazi S, Feldman RM. Control of intraocular inflammation associated with cataract surgery. Curr Opin Ophthalmol. 2001;12:4-8.
16. Laurell CG, Zetterstrom C. Effects of dexamethasone, diclofenac, or placebo on the inflammatory response after cataract surgery. Br J Ophthalmol. 2002;86:1380-1384.
17. Jaffe GJ, Schwartz D, Han DP, et al. Risk factors for postviterectomy fibrin formation. Am J Ophthalmol. 1990;109:661-667.
18. Heier J, Cheetham JK, Degryse R, et al. Ketorolac tromethamine 0.5% ophthalmic solution in the treatment of moderate to severe ocular inflammation after cataract surgery: a randomised, vehicle-controlled clinical trial. Am J Ophthalmol. 1999;127:253-259.
19. Kaminska-Olechnowicz B, Leszczynski R, Dworenko-Dworkin E, et al. Eye with implanted keratoprosthesis in ultrasound biomicroscopy. Klin Oczna. 1999;101:423-426.
20. Johnson RN, Blenkenship G. A prospective, randomized, clinical trial of heparin therapy for postoperative intraocular fibrin. Ophthalmology. 1988;95:312-317.
21. Iverson D, Katsura H, Hartzer MK, et al. Inhibition of intraocular fibrin formation following infusion of low-molecular-weight heparin during vitrectomy. Arch Ophthalmol 1991;109:405-409.
22. Williams GA, Lambrou FH, Jaffe GJ, et al. Treatment of postvitrectomy fibrin formation with intraocular tissue plasminogen activator. Arch Ophthalmol. 1988;106:1055-1058.
23. Jaffe GJ, Abrams GW, Williams GA, et al. Tissue plasminogen activator for postvitrectomy fibrin formation. Ophthalmology. 1990;97:184-189.
24. Lesser GR, Osher RH, Whipple D, et al. Treatment of anterior chamber fibrin following cataract surgery with tissue plasminogen activator. J Cataract Refract Surg. 1993;19:301-305.
25. Heiligenhaus A, Steinmetz B, Lapuente R, et al. Recombinant tissue plasminogen activator in cases with fibrin formation after cataract surgery: a prospective randomised multicentre study. Br J Ophthalmol. 1998;82: 810-815.
26. Lundy DC, Sidoti P, Winarko T, et al. Intracameral tissue plasminogen activator after glaucoma surgery. Ophthalmology. 1996;103: 274-282.
27. Zalta AH, Sweeney CP, Zalta AK, et al. Intracameral tissue plasminogen activator use in a large series of eyes with valved glaucoma drainage implants. Arch Ophthalmol. 2002;120:1487-1493.
28. Snyder RW, Sherman MD, Allinson RW. Intracameral tissue plasminogen activator for treatment of excessive fibrin response after penetrating keratoplasty. Am J Ophthalmol. 1990;109:483-484.
29. Mehta JS, Adams GGW. Recombinant tissue plasminogen activator following paediatric cataract surgery. Br J Ophtalmol. 2000;84:983-986.
30. Lim J, Maguire AM, John G, et al. Intraocular tissue plasminogen activator concentrations after subconjunctival delivery. Ophthalmology. 1992;100:373-376.
31. Azuara-Blanco A, Wilson RP. Intraocular and extraocular bleeding after intracameral injection of tissue plasminogen activator. Br J Ophthalmol. 1998;82:1345-1346.
32. Maeno T, Tano Y, Mano T, et al. Argatroban inhibits intraocular fibrin formation after vitrectomy in rabbits. Arch Ophthalmol. 2000;118:1401-1405.
33. Bath PE, Fridge DL, Robinson K, et al. Photometric evaluation of YAG-induced polymethylmethacrylate damage in a keratoprosthesis. Am Intraocular Implant Soc J. 1984;11:253-256.
34. Kim MK, Lee JL, Wee WR, et al. Seoul-type keratoprosthesis: preliminary results of the first 7 human cases. Arch Ophthalmol. 2002;120:761-766.
35. Kaminska-Olechnowicz B, Forminska-Kapuscik M, Leszczynski R. Use of Nd:YAG laser for disruption of retrocorneal membranes in eyes with implanted keratoprosthesis. Klin Oczna. 1997;99:91-93.
36. Ray S, Khan BF, Dohlman CH, et al. Management of vitreoretinal complications in eyes with permanent keratoprosthesis. Arch Ophthalmol. 2002;120:559-566.
37. von Fischern T, Langefeld S, Yuan L, et al. The "Aachen" keratoprosthesis: a new approach towards successful keratoprosthesis-surgery. Int J Artif Intern Org. 1999;22:52-57.
38. Kompa S, Redbrake C, Langefeld S, et al. The Type II Aachen- keratoprosthesis in humans: case report of the first prolonged application. Int J Artif Intern Org. 2001;24:110-114.
39. Legeais JM, Renard G, Parel JM, et al. Keratoprosthesis with biocolonizable microporous fluorocarbon haptic. Preliminary results in a 24-patient study. Arch Ophthalmol. 1995;113:757-763.
40. Legeais JM, Renard G. A second generation of artificial cornea (Biokpro II). Biomaterials. 1998;19:1517-1522.
41. Dudenhoefer EJ, Noun M, Gipson IK, et al. Histopathology of explanted collar button keratoprostheses: a clinicopathologic correlation. Cornea. 2003;22:424-428.
42. Aquavella JV, Rao GN, Brown AC, et al. Keratoprosthesis: Results, complications, and management. Ophthalmology. 1982;89:655-660.
43. Mortemousque B, Dorot N, Poirier L, et al. Complication of keratoprosthesis of posterior fixation: retroprosthetic membranes. Apropos of 4 cases. J Fr Ophtalmol. 1995;18:608-613.